sözaltı news Finance
Finance
EN AZ
3 Absurdly Cheap Growth Stocks to Buy Before the End of 2026

3 Absurdly Cheap Growth Stocks to Buy Before the End of 2026

finance.yahoo.com 15.09.2026 19:44 2 views

Tip: Try a valid symbol or a specific company name for relevant results A pro-grade research workspace with advanced charts, company data and real-time news. Now part of Yahoo Finance Gold.Learn more 3 Absurdly Cheap Growth Stocks to Buy Before the End of 2026 The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading.

Coinbase pays us for certain activity generated through this link. Prices displayed are informational. Investors looking for cheap stocks to buy before the end of 2026 don't have to look too far to find some great investments.

There are many top stocks that can make for solid long-term growth investments that are trading at absurdly cheap valuations right now. Three stocks that are trading at low earnings multiples and that have lots of growth still ahead are **Novo Nordisk**(NYSE:NVO), **Intuit**(NASDAQ:INTU), and **Reddit**(NYSE:RDDT). Here's why these can make for great growth stocks to buy right now. **_Missed Nvidia in 2009?

This Rare Signal Is Flashing Again._**_In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia._**_Continue »_** It's been a rough stretch for healthcare company Novo Nordisk, as it has declined about 23% in value over the past 12 months. Investors are questioning its ability to grow and compete alongside its rival, **Eli Lilly**.

Novo was an early leader in the GLP-1 race with Ozempic and Wegovy, but now has lost more than a couple of steps. The reason I'm not worried and remain invested in the stock, however, is that there are still ample growth opportunities ahead for Novo. A higher-dose version of Wegovy has shown that it can help people lose even more weight.

And the company is still in the early innings of the launch of its weight loss pill, which obtained approval from regulators late last year. Novo's sales have been underwhelming of late, and it has a new CEO working to turn things around. There's some uncertainty ahead, no doubt about that.

Extract — continue reading at the source.

Read full story